Reversion of the Anticoagulant Effect of the New Antithrombotic Agents Anti-Xa and Anti IIa by Non-specific Haemostatic Drugs,: an Ex-Vivo Study in Healthy Volunteers.

Trial Profile

Reversion of the Anticoagulant Effect of the New Antithrombotic Agents Anti-Xa and Anti IIa by Non-specific Haemostatic Drugs,: an Ex-Vivo Study in Healthy Volunteers.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 May 2012

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
  • Indications Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Thrombosis
  • Focus Pharmacodynamics
  • Acronyms REVNEWANTICO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top